Early prediction of response Functional imaging Microarrays Proteomics.

Slides:

Advertisements

Similar presentations

PreOP XRT: Oral fluoropyrimidines in randomized trials

Advertisements

Advances and Emerging Therapy for Lung Cancer

T Staging: Rectal cancer T1 invades submucosa T2 invades muscularis propria T3 invades subserosa or perirectal tissues T4 invades peritoneum, organs or.

Rectal Cancer: Advanced Technologies Chris Willett, M.D. Department of Radiation Oncology Duke University Medical Center Durham, NC.

JHSGR Neoadjuvant Therapy For Rectal Cancer Dr Chris TL Cheng Princess Margaret Hospital.

Pelvic Breakout Group. Purpose of meeting What is current status of radiation oncology technologies today. Where should we invest research resources to.

Staging. Treatment by Stage For early stage lung cancers, surgery or radiation alone For larger tumors (>4 cm) and N+, chemotherapy should be added.

Major sites of GIST metastases:

Management of early rectal carcinoma Joint Hospital Surgical Grand Round Jeren Lim United Christian Hospital.

Management of Locally Advanced Rectal Cancer Joint Hospital Surgical Grand Round Pamela Youde Nethersole Eastern Hospital Dr. YH Ling 19 May 2007.

Breast conservation in Locally advanced breast cancer Department of Endocrine Surgery College of Medicine Amrita Institute of Medical Sciences Kochi, Kerala.

Colon Cancer Daniel A. Nikcevich, MD, PhD Duluth Clinic Cancer Center January 26, 2009.

Molecular Cancer Targets Wester H Clin Cancer Res 2007;13:

Patterns of Care in Medical Oncology Neoadjuvant and Adjuvant Treatment of Rectal Cancer.

Chemoradiotherapy for Rectal cancer Dr. A. Sun Myint Lead Clinician GI Tumour Group Clatterbridge Centre for Oncology Association of Coloproctology of.

CLINICAL TRIALS WITH BIOLOGICAL ENDPOINT IN ESOGASTRIC CANCER

Brendan Moran Basingstoke OCTOBER 2008

Functional Imaging with PET for Sarcoma Rodney Hicks, MD, FRACP Director, Centre for Molecular Imaging Guy Toner, MD, FRACP Director, Medical Oncology.

Dan Spratt, MD Department of Radiation Oncology Neuroendocrine Prostate Cancer: FDG-PET and Targeted Molecular Imaging.

RTOG1106: Randomized Phase IIR Trial of Personalized Adaptive Radiotherapy Based on Mid-treatment FDG-PET in Locally Advanced NSCLC P.I.: Feng-Ming (Spring)

Radiotherapy for Colo-rectal Cancer. Case 1 בן 58 גידול בגובה 9 ס"ם מפי הטבעת קולונוסקופיה – גידול צירקולרי, כמעט חוסם TRUS T3 N0 מועמד לניתוח TME טיפול??

The Impact of Capecitabine and Oxaliplatin in the Preoperative Multimodality Treatment of Patients with Carcinoma of the Rectum: NSABP R-04 1 Capecitabine.

Preoperative chemoradiotherapy and postoperative chemotherapy with 5-FU and oxaliplatin versus 5-FU alone in locally advanced rectal cancer: First results.

Hypoxia in Soft-Tissue Sarcomas on [ 18 F]- Fluoroazomycin Arabinoside Positron Emission Tomography (FAZA-PET) Powerfully Predicts Response to Radiotherapy.

RT with TME surgery ? OUTLINEOUTLINE. Prostate Seminal vessels Neurovascular bundle Denonvilliers Fascia “holy plane” (Fascia rectalis) Total Mesorectal.

Demographic Characteristics of the Study Population - Part I Jenny N.Poynter et al N Engl J Med 2005;352:

Dr Francis Daniel, MB. ChB, FFR-RCSI, FRCR. Consultant in Clinical Oncology

How to integrate more effective systemic treatment into combined modality treatment?

T Staging: Rectal cancer T1 invades submucosa T2 invades muscularis propria T3 invades subserosa or perirectal tissues T4 invades peritoneum, organs or.

CapOx given concurrently to neoadjuvant RT improved pathologic response and tumor regression 2 in phase II trials. Synergy of cetuximab and RT has been.

Preliminary Results of the MRC CR07 / NCIC CO16 Randomized Trial Short course pre-op vs selective post-op chemo-RT for rectal cancer Local Recurrence after.

Patterns of Care in Medical Oncology Treatment of Metastatic Colon Cancer.

The Role of Preoperative Approaches in Localized Gastro Esophageal Cancers David H. Ilson, MD, PhD Gastrointestinal Oncology Service Memorial Sloan-Kettering.

Oxygen and Cancer: friend or foe?. Part 1: Scientific part Dirk de Ruysscher Part 2: Organisational part Harald Moonen.

Multidisciplinary treatment of rectal cancer. Medical oncology Carlo Aschele E.O. Ospedali Galliera – Genova - Italy Carlo Aschele E.O. Ospedali Galliera.

간담도 암에서의 PET 의 활용 핵의학과 홍일기. 18 F-FDG PET: Warburg effect.

Addition of Chemotherapy to Preoperative Radiotherapy Improves Outcomes in Rectal Cancer Slideset on: Bosset JF, Calais G, Mineur L, et al. Enhanced tumorocidal.

종양혈액내과 R4 고원진 / pf. 김시영 Rectal cancer : state of the art in 2012 Curr Opin Oncol 2012, 24:441–447.

Taipei Veterans General Hospital Practices Guidelines Oncology Rectal Cancer Version

Figure 4 PET imaging in experimental pancreatic cancer

Early postoperative complications are not increased in patients with rectal cancer treated with induction Capecitabine plus Oxaliplatin (CAPOX) followed.

Keith E. Kelly, MD and William H. Culbertson, MD

นายแพทย์ธราธร ตุงคะสมิต นายแพทย์ชำนาญการพิเศษ โรงพยาบาลมะเร็งอุดรธานี

Figure 2 Response after initial increase in total tumour burden

Case presented by Dr Moriarty

Figure 1 Carotid artery inflammation detected using 18F-FDG-PET

Figure 2 Multiscale modelling in oncology

Figure 2 New functional imaging techniques in lymphoma

Neoadjuvant therapy of rectal cancer – how can we make it better?

Figure 3 Intracranial targeting of high-grade gliomas

Colon Cancer Stages I-III

Effect of Neoadjuvant Concurrent Chemoradiotherapy on Locally Advanced Middle and Low Rectal Cancer— A Propensity Score Matching Study 官泰全,林春吉,楊純豪,姜正愷,林宏鑫,藍苑慈,

Avinash Kambadakone Ramesh1

Figure 2 Differences between MC and AC

Do we need post-operative CHEMOTHERAPY in patients with PATHOLOGIC Complete Response to neoadjuvant therapy in RECTAL CANCER ? Philippe Rougier ESDO Board(European.

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Carotid artery inflammation detected using 68Ga-DOTATATE-PET

Capecitabine versus 5-fluorouracil-based (neo-)adjuvant chemoradiotherapy for locally advanced rectal cancer: safety results of a randomized phase III.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Metabolic response by 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT). a) FDG PET/CT for patient 2 at baseline.

Representative CT and PET/CT images of three patients with NSCLCs

Algorithms for the management of metastatic colorectal cancer: (A) resectable metastatic disease; (B) metastatic disease, first-line; (C) metastatic disease,

Do all patients with T2-3 mid-high rectal adenocarcinomas require RT as part of their neoadjuvant therapy? - Yes -   Bruce Minsky.

Figure 1 Overview of the imaging biomarker roadmap

Noninvasive detection of acquired MET amplification as a mechanism of afatinib/trastuzumab resistance using cfDNA. Noninvasive detection of acquired MET.

A 63-year-old female with lung adenocarcinoma treated with nivolumab, who experienced pseudoprogression. A 63-year-old female with lung adenocarcinoma.

A, pretreatment CT scan of pelvic lymphadenopathy (identified by white arrow) in 1 patient with documented response to 1α-OH-D2. A, pretreatment CT scan.

A, Selected 4 quantitative imaging features significantly associated with 3 imaging subtypes, including tumor volume, tumor sphericity, tumor homogeneity.

Presentation transcript:

Early prediction of response Functional imaging Microarrays Proteomics

N=15 N=10N=5 Before RT During RT After RT Before RTDuring RTAfter RTBefore RTDuring RTAfter RT FDG ,54,51483 FMISO533 FLT831,5 tumour evolution: SUVmax

RECTUM GELATINE Rectum resection Styrofoam box Orientation sticks -20°C Formol scan 4 mm slices Validation of tumor delineation

Validation of Tumor Delineation T T T

MR CT FDG PET FLT PET Resection specimenPathology metabolism tracerproliferation tracer before therapy during therapy after therapy

T P Validation tumour volume MR-FDG with APO FDG-PET TVs delineated with the gradient-based method matched closer with the pathological TV than MR-based TV

Translational research in rectal cancer S SURGERY W T0T1T2 Blood/ tissue samples

Pathological response according to tumor regression grading ChemoradiationCetuximab* + capecitabine (n=37) Oxaliplatin* + capecitabine (n=36) 5-FU alone (n=35) pCR 2 (5%) 5 (14%) 4 (11%) > 2 mm mesorectal margin 27 (73%) 30 (83%)

Translational research in rectal cancer Micro-arrays Immunohistochemistr y FISH GENESPROTEINS ELISA

Phase II study with cetuximab in rectal cancer TGF-α EGFR Fibro- inflammatory changes Ki67 Debucquoy et al, unpublished results

Effect of Bevacizumab on tumour response Marked response in all 6 patients Only microscopic disease in 5 patients Willett et al. J Clin Oncol 2005

Effect of bevacizumab on tumour vasculature Pretreatment Day 12 Patient IFP (mm Hg) IFP = interstitial fluid pressure Willett et al. Nat Med 2004